全文获取类型
收费全文 | 2361篇 |
免费 | 83篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 19篇 |
儿科学 | 40篇 |
妇产科学 | 24篇 |
基础医学 | 353篇 |
口腔科学 | 14篇 |
临床医学 | 157篇 |
内科学 | 677篇 |
皮肤病学 | 95篇 |
神经病学 | 188篇 |
特种医学 | 90篇 |
外科学 | 417篇 |
综合类 | 20篇 |
一般理论 | 3篇 |
预防医学 | 134篇 |
眼科学 | 26篇 |
药学 | 95篇 |
中国医学 | 3篇 |
肿瘤学 | 91篇 |
出版年
2023年 | 9篇 |
2022年 | 20篇 |
2021年 | 45篇 |
2020年 | 33篇 |
2019年 | 30篇 |
2018年 | 43篇 |
2017年 | 31篇 |
2016年 | 38篇 |
2015年 | 33篇 |
2014年 | 61篇 |
2013年 | 82篇 |
2012年 | 121篇 |
2011年 | 161篇 |
2010年 | 74篇 |
2009年 | 82篇 |
2008年 | 132篇 |
2007年 | 176篇 |
2006年 | 152篇 |
2005年 | 151篇 |
2004年 | 121篇 |
2003年 | 82篇 |
2002年 | 102篇 |
2001年 | 25篇 |
2000年 | 22篇 |
1999年 | 29篇 |
1998年 | 25篇 |
1997年 | 10篇 |
1996年 | 16篇 |
1995年 | 21篇 |
1994年 | 23篇 |
1993年 | 12篇 |
1990年 | 9篇 |
1989年 | 10篇 |
1978年 | 9篇 |
1960年 | 10篇 |
1958年 | 9篇 |
1943年 | 9篇 |
1936年 | 10篇 |
1935年 | 8篇 |
1933年 | 13篇 |
1932年 | 12篇 |
1931年 | 11篇 |
1930年 | 9篇 |
1929年 | 10篇 |
1928年 | 9篇 |
1927年 | 15篇 |
1926年 | 13篇 |
1925年 | 15篇 |
1924年 | 14篇 |
1911年 | 11篇 |
排序方式: 共有2446条查询结果,搜索用时 31 毫秒
41.
Constanze A. Jakwerth Adam M. Chaker Ferdinand Guerth Madlen Oelsner Lisa Pechtold Lynn S. zur Bonsen Julia T. Ullmann Susanne Krauss-Etschmann Anna Erb Josephine Kau Mirjam Plaschke Marlene Winkler Alexandra Kurz Antonia Kloss Julia Esser-von Bieren Carsten B. Schmidt-Weber Ulrich M. Zissler 《Clinical and experimental allergy》2021,51(12):1577-1591
42.
Long‐term outcome of belatacept therapy in de novo kidney transplant recipients – a case‐match analysis 下载免费PDF全文
Christoph Schwarz Sophie Mayerhoffer Gabriela A. Berlakovich Rudolf Steininger Thomas Soliman Bruno Watschinger Georg A. Böhmig Farsad Eskandary Franz König Ferdinand Mühlbacher Thomas Wekerle 《Transplant international》2015,28(7):820-827
While belatacept has shown favorable short‐ and midterm results in kidney transplant recipients, only projections exist regarding its potential impact on long‐term outcome. Therefore, we performed a retrospective case‐match analysis of the 14 belatacept patients originally enrolled in the phase II multicenter trial at our center. Fifty six cyclosporine (CyA)‐treated patients were matched according to age at transplantation, first/retransplant, and donor type. Ten years after kidney transplantation, kidney function remained superior in belatacept‐treated patients compared with the CyA control group. Moreover, none of the belatacept‐treated patients had donor‐specific antibodies ≥10 years post‐transplantation compared with 38.5% of tested CyA‐treated subject (0/10 vs. 5/13; P = 0.045). Notably, however, patient and graft survival was virtually identical in both groups (71.4% vs. 71.3%; P = 0.976). In the present single‐center study population, patients treated with belatacept demonstrated a patient and graft survival at 10 years post‐transplant which was comparable to that of similarly selected CNI‐treated patients. Larger studies with sufficient statistical power are necessary to definitively determine long‐term graft survival with belatacept. 相似文献
43.
Total Reconstitution of Functionally Active 50S Ribosomal Subunits from Escherichia coli 总被引:16,自引:4,他引:16 下载免费PDF全文
Knud H. Nierhaus Ferdinand Dohme 《Proceedings of the National Academy of Sciences of the United States of America》1974,71(12):4713-4717
Total reconstitution of 50S subunits from E. coli was achieved by a two-step incubation procedure. In the first step, 23S RNA, 5S RNA, and the total proteins from 50S subunits were incubated for 20 min at 40 degrees in the presence of 4 mM Mg(++) and 400 mM NH(4)Cl. In the second step, the Mg(++) concentration was raised to 20 mM and the incubation was performed for 90 min at 50 degrees . No requirement for 30S subunits or other components (e.g., polyamine) was found. The reconstituted particle has the same sedimentation coefficient as the native 50S subunit and is highly active in protein synthesis with natural (R17 RNA) and artificial [poly(U)] messengers as well as in tests for peptidyltransferase (fragment assay) and for binding of antibiotics (chloramphenicol). 相似文献
44.
Mutations of p53 Tumor Suppressor Gene, Apoptosis, and Proliferation in Intrahepatic Cholangiocellular Carcinoma of the Liver 总被引:4,自引:0,他引:4
Tannapfel A Weinans L Geissler F Schütz A Katalinic A Köckerling F Hauss J Wittekind C 《Digestive diseases and sciences》2000,45(2):317-324
This study was performed to examine the correlation between mutations of the p53 tumor suppressor gene, the occurrence of apoptosis, and proliferation in cholangiocellular carcinoma of the liver. The results obtained were compared with pathohistological stage (according to UICC) and grade and with disease related survival rate. In 41 curatively (R0–) resected intrahepatic cholangiocellular carcinomas, the status of the p53 gene was determined by direct sequencing of exons 4–9 and immunohistochemically. Apoptosis was assessed using the in situ end labeling (ISEL) technique in combination with morphological criteria. Proliferation was analyzed by immunohistochemistry of MIB-1 (Ki-67), Proliferating cell nuclear antigen (PCNA), and silver-stained nucleolar organizer regions (AgNOR). The results obtained were compared with pathohistological stage (according to UICC), grade, several other histopathological factors, and survival rate. Mutations of p53 were detected in 15/41 carcinomas examined (37%). The most common change was a GC and CT transition, changing the hot spot amino acid determined by exons 4–8. Of these 15 tumors, 14 were also p53-positive by immunohistochemistry. In each carcinoma examined, we could demonstrate MIB-1, PCNA, and AgNOR dots and also apoptotic cells in variable proportions. The proliferation markers showed a significant correlation among themselves. In univariate survival analysis, the extent of the primary tumor, lymph node status, grade, and p53 were significant factors influencing patient survival. Performing multivariate Cox regression survival analysis, however, only the extent of primary tumor and lymph node status had an independent prognostic impact. Apoptosis was not related to patient prognosis or to other parameters examined. In conclusion, these results indicated that p53 could serve as an additional prognostic parameter that could provide auxiliary information for patient outcome. However, tumor stage and lymph node involvement were the strongest prognostic factors. We failed to establish apoptosis or other pathological parameters as factors predicting the prognosis of patients with cholangiocellular carcinoma. 相似文献
45.
46.
Sreekanth Vemulapalli Jamy Ard George L. Bakris Deepak L. Bhatt Alan S. Brown William C. Cushman Keith C. Ferdinand John M. Flack Jerome L. Fleg Barry T. Katzen John B. Kostis Suzanne Oparil Chet B. Patel Carl J. Pepine Ileana L. Piña Krishna J. Rocha-Singh Raymond R. Townsend Eric D. Peterson Robert M. Califf Manesh R. Patel 《American heart journal》2014
47.
Benedikt Bosbach Shayu Deshpande Ferdinand Rossi Jae-Hung Shieh Gunhild Sommer Elisa de Stanchina Darren R. Veach Joseph M. Scandura Katia Manova-Todorova Malcolm A. S. Moore Cristina R. Antonescu Peter Besmer 《Proceedings of the National Academy of Sciences of the United States of America》2012,109(34):E2276
48.
49.
50.